Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Polymorphism of p53 Gene Codon 72 in Endometrial Cancer: Correlation with Tumor Grade and Histological Type

  • Published : 2014.12.18
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Endometrial cancer is the fourth most common cancer among women in developed countries. Patients with endometrial cancer may benefit from systemic chemotherapy alone or in combination with targeted therapies if the disease is clinically diagnosed prior to spread and metastasis to other organs. The aim of this study was to evaluate the prognostic role of p53 polymorphism and its correlation with tumor grade in human uterine endometrial carcinomas. Materials and Methods: A total of 75 patients with endometrial carcinomas were studied for possible mutations in exon 4 of the p53 gene using polymerase chain reaction and restricting fragment length polymorphism techniques and sequencing. Results: In recent study, The rate of homozygote genotype of pro/pro or Arg/Arg in high grade group was higher than in comparison with low grade one. In addition samples that were undigested in RFLP, showed mutation in exone 4. Conclusions: Our findings showed that high grade endometrial carcinomas are highly associated with TP53 polymorphisms in comparison with low grades.

Keywords

References

  1. Ashton KA, Proietto A, Otton G, et al (2009). Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer. Gynecol Oncol, 113, 109-14. https://doi.org/10.1016/j.ygyno.2008.12.036
  2. Bai L, Zhu WG (2006). p53: structure, function and therapeutic applications. J Cancer Mol, 2, 141-53.
  3. Balik G, Kagitci M, Ustuner I, et al (2013). Which endometrial pathologies need intraoperative frozen sections? Asian Pac J Cancer Prev, 14, 6121-5. https://doi.org/10.7314/APJCP.2013.14.10.6121
  4. Dobrzycka B, Terlikowski SJ, Mazurek A, et al (2010). Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancer. Int J Cancer, 127, 612-21. https://doi.org/10.1002/ijc.25077
  5. Francisco G, Menezes PR, Eluf-Neto J, Chammas R (2011). Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case-control studies. Int J Cancer, 129, 920-30. https://doi.org/10.1002/ijc.25710
  6. Garcia-Dios DA, Lambrechts D, Coenegrachts L, et al (2013). High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma. Gynecol Oncol, 128, 327-34. https://doi.org/10.1016/j.ygyno.2012.11.037
  7. Harris N, Brill E, Shohat O, et al (1986). Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol, 6, 4650-6.
  8. Hecht JL, Mutter GL (2006). Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol, 24, 4783-91. https://doi.org/10.1200/JCO.2006.06.7173
  9. Hernandez E, ObermairA, Hoskins PJ, Magrina JF, McLellan R (2010). Controversies in the management of endometrial cancer. Obstet Gynecol Int, 894587.
  10. Hu Z, Li X, Qu X, et al (2010). Intron 3 16 bp duplication polymorphism of TP53 contributes to cancer susceptibility: a meta-analysis. Carcinogenesis, 31, 643-7. https://doi.org/10.1093/carcin/bgq018
  11. Hui P, Kelly M, O'Malley DM, Tavassoli F, Schwartz PE (2005). Minimal uterine serous carcinoma: a clinicopathological study of 40 cases. Modern Pathology, 18, 75-82. https://doi.org/10.1038/modpathol.3800271
  12. Jiang DK, Yao L, Ren WH (2011). TP53 Arg72Pro polymorphism and endometrial cancer risk: a meta-analysis. Med Oncol, 28, 1129-35. https://doi.org/10.1007/s12032-010-9597-x
  13. Lee E J, Kim TJ, Kim DS (2010). p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review. Gynecol Oncol, 116, 533-8. https://doi.org/10.1016/j.ygyno.2009.11.018
  14. Levine RL, Cargile CB, Blazes MS (1998). PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer research, 58, 3254-8.
  15. Matei MC, Negura L, Liliac L, Negura A, Azoicai D (2012). Validation of PCR-RFLP techniques for the evaluation of codon 72 of p53 and CYP1A1 gene's polymorphisms in relation with ovarian cancer in a Romanian population. Rom J Morphol Embryol, 53, 47-54.
  16. Niwa Y, Hirose K, Matsuo K, et al (2005). Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53 Arg72Pro polymorphism with the risk of endometrial cancer in Japanese subjects. Cancer letters, 219, 183-90. https://doi.org/10.1016/j.canlet.2004.10.018
  17. Oda K, Stokoe D, Taketani Y, McCormick F (2005). High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res, 65, 10,669-73.
  18. Rowlands IJ, Lee C, Janda M, et al (2013). Predicting positive and negative impacts of cancer among long-term endometrial cancer survivors. Psycho-Oncology, 22, 1963-71. https://doi.org/10.1002/pon.3236
  19. Saghir FS, Rose IM, Dali AZ, et al (2010). Gene expression profiling and cancer-related pathways in type I endometrial carcinoma. Int J Gynecol Cancer, 20, 724-31. https://doi.org/10.1111/IGC.0b013e3181e1c14c
  20. Salvesen HB, Carter SL, Mannelqvist M, et al (2009). Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci USA, 106, 4834-9. https://doi.org/10.1073/pnas.0806514106
  21. Santin AD, Zhan F, Cane S, et al (2005). Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. Br J Cancer, 92, 1561-73. https://doi.org/10.1038/sj.bjc.6602480
  22. Ueda M, Terai Y, Kanda K, et al (2006). Germline polymorphism of p53 codon 72 in gynecological cancer. Gynecologic oncology, 100, 173-8. https://doi.org/10.1016/j.ygyno.2005.08.015
  23. Zubor P, Stanclova A, Kajo K, et al (2009). The p53 codon 72 exon 4 BstUI polymorphism and endometrial cancer in Caucasian women. Oncology, 76, 173-83. https://doi.org/10.1159/000201570

Cited by

  1. No Evidence of Association of the Arg72Pro p53 Gene Polymorphism with Cancer Risk in the Saudi Population: a Meta-Analysis vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5663
  2. Accuracy of Sentinel Node in Detecting Lymph Node Metastasis in Primary Endometrial Carcinoma vol.16, pp.15, 2015, https://doi.org/10.7314/APJCP.2015.16.15.6691
  3. C-kit Mutations in Endometrial Cancer: Correlation with Tumor Histologic Type vol.16, pp.17, 2015, https://doi.org/10.7314/APJCP.2015.16.17.7449
  4. Effect of p53β on human gastric cancer cells treated with recombinant mutated human TNF and cisplatin vol.15, pp.6, 2017, https://doi.org/10.3892/mmr.2017.6436
  5. No association of TP53 codon 72 and intron 3 16-bp duplication polymorphisms with breast cancer risk in Chinese Han women: new evidence from a population-based case–control investigation vol.23, pp.1, 2018, https://doi.org/10.1186/s40001-018-0345-6